Nicolet Bankshares Inc. trimmed its stake in Pfizer Inc. (NYSE:PFE) by 3.9% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 37,413 shares of the biopharmaceutical company’s stock after selling 1,504 shares during the period. Nicolet Bankshares Inc.’s holdings in Pfizer were worth $1,344,000 at the end of the most recent reporting period.
Other large investors also recently bought and sold shares of the company. Bath Savings Trust Co grew its holdings in Pfizer by 3.4% during the 2nd quarter. Bath Savings Trust Co now owns 17,217 shares of the biopharmaceutical company’s stock valued at $746,000 after buying an additional 564 shares in the last quarter. Cox Capital Mgt LLC grew its holdings in Pfizer by 1.5% during the 2nd quarter. Cox Capital Mgt LLC now owns 37,986 shares of the biopharmaceutical company’s stock valued at $1,646,000 after buying an additional 565 shares in the last quarter. Thomasville National Bank grew its holdings in Pfizer by 4.1% during the 2nd quarter. Thomasville National Bank now owns 76,628 shares of the biopharmaceutical company’s stock valued at $3,319,000 after buying an additional 3,001 shares in the last quarter. Park National Corp OH grew its holdings in Pfizer by 27.6% during the 2nd quarter. Park National Corp OH now owns 252,546 shares of the biopharmaceutical company’s stock valued at $10,941,000 after buying an additional 54,642 shares in the last quarter. Finally, Deane Retirement Strategies Inc. grew its holdings in Pfizer by 1.8% during the 2nd quarter. Deane Retirement Strategies Inc. now owns 51,699 shares of the biopharmaceutical company’s stock valued at $2,240,000 after buying an additional 894 shares in the last quarter. 71.66% of the stock is owned by institutional investors and hedge funds.
PFE has been the subject of a number of recent analyst reports. Morgan Stanley reduced their target price on Pfizer from $40.00 to $38.00 and set an “equal weight” rating for the company in a report on Tuesday, August 27th. Zacks Investment Research raised Pfizer from a “sell” rating to a “strong-buy” rating and set a $38.00 target price for the company in a report on Tuesday, October 1st. ValuEngine raised Pfizer from a “sell” rating to a “hold” rating in a report on Wednesday, October 2nd. UBS Group reaffirmed a “neutral” rating and set a $43.00 target price on shares of Pfizer in a report on Monday, August 5th. Finally, Credit Suisse Group reaffirmed a “neutral” rating on shares of Pfizer in a report on Monday, August 12th. Twelve analysts have rated the stock with a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the stock. The company presently has a consensus rating of “Hold” and an average price target of $44.47.
In other news, major shareholder Pfizer Inc bought 50,000 shares of the company’s stock in a transaction that occurred on Tuesday, September 17th. The stock was bought at an average price of $18.00 per share, for a total transaction of $900,000.00. The acquisition was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Scott Gottlieb bought 3,000 shares of the company’s stock in a transaction that occurred on Friday, August 23rd. The stock was purchased at an average price of $34.72 per share, with a total value of $104,160.00. Following the transaction, the director now directly owns 3,000 shares in the company, valued at $104,160. The disclosure for this purchase can be found here. Company insiders own 0.09% of the company’s stock.
Shares of PFE traded up $0.24 during trading hours on Wednesday, reaching $36.67. 590,701 shares of the company’s stock traded hands, compared to its average volume of 15,835,454. The stock has a market cap of $201.66 billion, a PE ratio of 12.23, a price-to-earnings-growth ratio of 2.16 and a beta of 0.66. The company has a current ratio of 1.47, a quick ratio of 1.21 and a debt-to-equity ratio of 0.60. The firm’s 50 day simple moving average is $36.28 and its 200-day simple moving average is $39.61. Pfizer Inc. has a 12 month low of $33.97 and a 12 month high of $46.47.
Pfizer (NYSE:PFE) last issued its quarterly earnings results on Monday, July 29th. The biopharmaceutical company reported $0.80 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.75 by $0.05. The firm had revenue of $13.26 billion during the quarter, compared to the consensus estimate of $13.43 billion. Pfizer had a return on equity of 28.10% and a net margin of 23.58%. The company’s revenue for the quarter was down 1.5% on a year-over-year basis. During the same quarter last year, the company posted $0.77 EPS. As a group, analysts expect that Pfizer Inc. will post 2.82 earnings per share for the current fiscal year.
The firm also recently declared a quarterly dividend, which will be paid on Monday, December 2nd. Stockholders of record on Friday, November 8th will be given a dividend of $0.36 per share. The ex-dividend date of this dividend is Thursday, November 7th. This represents a $1.44 dividend on an annualized basis and a dividend yield of 3.93%. Pfizer’s dividend payout ratio (DPR) is presently 48.00%.
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.
Recommended Story: When is a capital gain realized?
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.